Table 2.
Known experimental verification of approved HIV-1 and HBV drugs.
| Drugs | Experimental Factor Ontology (EFO) Terms | Max Phase for Indication * | References |
|---|---|---|---|
| tenofovir | HIV-1 infection | 3 | [37] |
| tenofovir | Hepatitis B virus infection | 3 | [38], FDA |
| hepsera | Chronic hepatitis B virus infection | 4 | [39], |
| hepsera | Hepatitis B virus infection | 4 | [40], FDA |
| hepsera | HIV infection | 3 | [41] |
| adefovir | HIV infection | 1 | [42] |
| adefovir | Hepatitis B virus infection | 3 | [40], FDA |
| tenofovir alafenamide | HIV-1 infection | 4 | [43] |
| tenofovir alafenamide | Hepatitis B virus infection | 4 | [44], FDA |
| interferon alfa-2b | HIV-1 infection | 3 | [45] |
| interferon alfa-2b | Hepatitis B virus infection | 4 | [46], FDA |
| abacavir | HIV-1 infection | 4 | [47], FDA |
| emtricitabine | HIV-1 infection | 4 | [48], FDA |
| emtricitabine | Hepatitis B virus infection | 3 | [49] |
| ritonavir | Hepatitis B virus infection | 2 | [50] |
| ritonavir | HIV-1 infection | 4 | [51], FDA |
*: Denotes the maximum phase of development for the compounds across all indications.